Financials
Financial year 2025
Worth noting
- A loss two years in a row.
Revenue
€ 176,727
▼ 86% vs 2024
Profit
Caution€ -17.4 million
▼ 54% vs 2024
Debts
Low€ 4.5 million
▲ 8% vs 2024
Confo Therapeutics from Gent, company number BE0632474939, closed financial year 2025 with a result of € -17.4 million after tax. For that financial year Confo Therapeutics recorded revenue of € 176,727 and equity of € 33.3 million. Compared with financial year 2024, the result moved from € -11.3 million to € -17.4 million. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 8, 2026.
What happened at Confo Therapeutics?
What happened at Confo Therapeutics in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- WELLINGTON PARTNERS LIFE SCIENCES V GMBH & CO. KG stepped down as director. NBB
- Jeroen VANGINDERTAEL stepped down as director. NBB
- Caroline GODDEERIS stepped down as director. NBB
- Edward VAN WEZEL stepped down as director. NBB
- Cedric VERVERKEN stepped down as director. NBB
- Dieter WEINAND stepped down as director. NBB
- Robert SCOTT stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 17.4 million. Source: NBB ↗
In short
From € 9.9 million loss in 2021 to € 17.4 million loss in 2025.
Best year ever: 2023, with € 31.1 million profit.
Pays suppliers within 47 days on average.
A new publication or filing at Confo Therapeutics? We notify you, reason included.
Follow Confo TherapeuticsNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
The shares are held by BGV3PoolCo 5 (13.7%), Fund+ NV (11.6%), Wellington Partners Life Sciences V GmbH & Co. KG (11.5%), Capricorn Health-Tech Fund NV (9.9%), V-Bio Fund 1 NV (8.9%) and AvH Growth Capital (7.3%).
Directors
According to the 2025 annual accounts
WELLINGTON PARTNERS LIFE SCIENCES V GMBH & CO. KG
Director · represented by Varun GUPTA
since 2021 · until 2030
Jeroen VANGINDERTAEL
Director
since 2024 · until 2030
Caroline GODDEERIS
Director
since 2022 · until 2030
Dieter WEINAND
Director
since 2023 · until 2027
Edward VAN WEZEL
Director
since 2019 · until 2030
Robert SCOTT
Director
since 2020 · until 2027
Cedric VERVERKEN
Managing director
since 2016 · until 2030
Shareholders
13.7%
11.6%
Wellington Partners Life Sciences V GmbH & Co. KG
11.5%
8.9%
7.3%
5.9%
Perceptive Life Sciences Master Fund Ltd
3.8%
3.6%
2.9%
2.2%
1.9%
John BERRIMAN
0.6%
0.5%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Technologiepark-Zwijnaarde 30
9052 Gent
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 3 companies are registered at this address.
Website
Technologies
Hosting & Email
Email provider
Microsoft 365
Hosting
CLOUDFLARESPECTRUM Cloudflare, Inc., US
Domain
Domain
confotherapeutics.com
Registered
2014-05-27
Registrar
Ascio Technologies, Inc. Danmark - Filial af Ascio technologies, Inc. USA
Expires
2026-05-27
Website info
Features
Security
Network
Details
- Company number
- 0632.474.939
- VAT number
- BE 0632.474.939
- Registered office
- Technologiepark-Zwijnaarde 30, 9052 Gent
- Names & denominations
- Confo Therapeutics · Confo
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 11 June 2015
- Peppol
- Active · Active since 16 Jul 2025
- Contact
- confotherapeutics.com
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied